<p fr-original-style="" style="margin-top: 0px; margin-bottom: 1em; box-sizing: border-box;">• <a fr-original-style="" href="https://www.reuters.com/markets/europe/exclusive-polish-drug-maker-polpharma-working-bid-advents-zentiva-sources-2022-01-20/" rel="noopener noreferrer" style="color: rgb(9, 9, 9); text-decoration: none; background-color: transparent; outline: none; cursor: pointer; transition: color 0.3s ease 0s; touch-action: manipulation; user-select: auto; box-sizing: border-box;" target="_blank"><strong fr-original-style="" style="font-weight: 700; box-sizing: border-box;">Poland's largest drugmaker Polpharma</strong></a> is reportedly looking into a prospective $4 billion (€3.5bn) takeover of its Czech rival Zentiva, offering investors in return a minority stake in Advent International, a global private equity firm who bought Zentiva for €1.9 billion from Sanofi in 2018, and has hired JPMorgan to select potential investors.</p>

Polpharma ile ilgili hikayeler